Business Wire

Istanbul Based Promena, Ranked Among Top 50 Global Procurement Providers

Share

Promena, an Istanbul-based provider of strategic procurement software, has been included – for the second time – on Spend Matters’ list of “50 Procurement Providers to Watch” in the year ahead. A leading source of intelligence for the global procurement industry, Spend Matters releases its list every year.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211109005838/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Istanbul based Promena, Ranked Among Top 50 Global Procurement Providers (Graphic: Business Wire)

“We are proud to be the first and only Turkish company to be included in the list, which serves to confirm Promena’s leading position in today’s rapidly-changing global procurement ecosystem,” Orçun Güven, Zer Sales and Promena Services Director, says.

Turkey’s First Global-Procurement Firm
Promena is owned and managed by Zer, a subsidiary of Turkey’s Koç Holding that specializes in strategic procurement and sourcing management. First launched in 2001, Promena offers a range of procurement services for the 21st century, including e-sourcing, e-procurement, expense analysis, and supplier information management.

“Turkey’s first global-procurement company, Promena helps businesses save money and time by digitalizing their procurement processes and providing end-to-end supply-chain solutions,” Güven explains. Along with Spend Matters’ “50 to Watch” list, Promena was featured in Capgemini’s latest Digital Procurement Research Report, and was also recently cited as a “Product Challenger” in the ISG Provider Lens Quadrant research series and Spend Matters SolutionMap report.

Turkey: Vital Link in Global Supply Chain
Due to pandemic-induced supply disruptions, Turkey has assumed an increasingly prominent role in the global supply matrix. Over the course of the last two years, a growing number of international brands have come to rely on Promena’s far-flung distribution network, which extends from India to Latin America.

Güven points to recent assertions by credit-rating agency Fitch that Turkey – more than any other country – had the most to gain from shifting global supply lines. “Europe, the Middle East, North Africa and Central Asia are all easily accessible from Turkey,” he says, noting that these regions account for a collective population of 1.3 billion and a combined GDP of some $26 trillion.

The pandemic has also served to accelerate the digitalization of global supply processes, Güven adds. “If businesses hope to compete internationally, they must ensure the sustainability of their operations,” he says. “Promena can help businesses deal with the digital transformation by finding – and implementing – sustainable solutions to all their most pressing procurement needs.”

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Tülay Genç
info@b2press.com
+31(30) 799 6022

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology27.4.2024 03:09:00 EEST | Press release

ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem. GanNA founders Carolyn Bertozzi, Ph.D., and Richard D. Cummings, Ph.D, will now serve as advisors to ReNAgade. “ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade. “Delivery is foundational to ReNAgade’s mission to overcome the current limitations of RNA medicines. We believe the technology developed within GanNA will help further solidify ReNAgade’s leadership position as we continue advancing our unique, integrated therapeutic platform.” Formed in 2021 and invested in by ReNAgade, GanNA Bio ha

HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 23:06:00 EEST | Press release

HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 19:03:00 EEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 18:43:00 EEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 18:22:00 EEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/ Contact information Hawthorn Advisors suzano@hawthornadvisors.com

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye